Navigation Links
Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
Date:10/20/2010

CHADDS FORD, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter 2010 financial results on November 1, 2010 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results.  

David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 866-788-0543 (domestic) or 857-350-1681 (international) and enter passcode 81013739.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from November 1 at 1:00 p.m. ET until 12:00 a.m. ET on November 9 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 88788586.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 a.m. ET on November 9.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics, Inc., please visit www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
2. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
3. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
4. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
5. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
7. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
8. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
9. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
10. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
11. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells ... Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, ... moved to NYC when she was three. At six, they moved to Dayton, Ohio, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
Breaking Medicine News(10 mins):